CRON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRON is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some improving revenue growth and a favorable analyst initiation, but the technical setup is weak, earnings are near-term, and profitability remains negative. With no strong Intellectia buy signal and no clear momentum breakout, the better call is to wait rather than buy immediately.
The current trend is mildly weak. CRON closed at 2.55, below the prior close of 2.57, with regular market performance down 1.91%. MACD histogram is negative and expanding, which signals weakening momentum. RSI_6 at 35.54 is near oversold but not yet a strong reversal signal. Moving averages are converging, suggesting indecision rather than a confirmed uptrend. Price is also trading below the pivot at 2.636, with support at 2.564 and 2.519 and resistance at 2.709 and 2.754. Overall, this is a neutral-to-bearish setup, not an attractive immediate entry.
["TD Securities initiated coverage with a Buy rating and a C$4.50 price target, which is well above the current share price.", "Revenue in 2025/Q4 rose 46.96% YoY, showing strong top-line growth.", "Gross margin improved to 35.45%, up 3.87% YoY.", "Cronos launched Spinach STIX pre-rolls across Canada, which could support brand momentum and sales growth.", "Options positioning is bullish with very low put-call ratios."]
["Net income was still negative at -1.816 million in 2025/Q4 and worsened YoY.", "EPS fell to 0 from the prior year level, showing no earnings progress.", "MACD momentum is negative and expanding.", "The stock is trading below pivot resistance support structure with no confirmed breakout.", "No significant hedge fund, insider, or congress trading trends are present to reinforce confidence.", "Earnings are scheduled for 2026-05-11 pre-market, creating event risk before the next clear fundamental update."]
In 2025/Q4, Cronos showed strong revenue growth, with sales rising to 44.53 million, up 46.96% year over year. Gross margin also improved to 35.45%, which is a positive operational sign. However, profitability remains weak because net income stayed negative at -1.816 million and EPS dropped to 0. For a long-term beginner investor, the business is improving at the top line but still not demonstrating consistent bottom-line strength.
Recent analyst sentiment is constructive. TD Securities initiated coverage on 2026-02-24 with a Buy rating and C$4.50 target, implying meaningful upside from the current price. The bull case is that Cronos has recognizable cannabis brands, improving profitability potential, and a relatively lean cost base. The bear case is that the company is still not profitable, and the stock has not yet confirmed a strong technical uptrend. Wall Street pros are positive on valuation upside and brand positioning, but cautious on execution and earnings quality.
